Lipopeptide stimulation of MHC class I-restricted memory cytotoxic T lymphocytes from equine infectious anemia virus-infected horses

Vaccine

Volumn 20, Issue 13-14, 2002, Pages 1809-1819

  Ridgely, Sherritta L ^a   McGuire, Travis C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cytotoxic T lymphocyte epitope; Equine infectious anemia; Lipopeptide

Indexed keywords

ALLOANTIGEN; ARGINYLVALYLGLUTAMYLASPARTYLVALYLTHREONYLASPARAGINYLTHREONYLALANYLGLUTAMYLT YROSYLTRYPTOPHAN; CYSTEINE DERIVATIVE; EPITOPE; GLYCYLTHREONYLTHREONYLLYSYLGLUTAMINYLLYSYLMETHIONYLMETHIONYLLEUCINE; HISTIDYLPROLYLLEUCYLPROLYLASPARAGINYLALANYLPROLYLLEUCYLVALINE; LEUKOCYTE ANTIGEN; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRIPALMITOYLGLYCERYLCYSTEINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EQUINE INFECTIOUS ANEMIA VIRUS; EVALUATION; HORSE; HORSE DISEASE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MONONUCLEAR CELL; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TARGET CELL; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; CYSTEINE; EPITOPES; EQUINE INFECTIOUS ANEMIA; GENE PRODUCTS, ENV; HISTOCOMPATIBILITY ANTIGENS CLASS I; HORSES; IMMUNOLOGIC MEMORY; INFECTIOUS ANEMIA VIRUS, EQUINE; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VIRAL CORE PROTEINS;

EID: 0037086696     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00517-5     Document Type: Article

References (57)

1. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
2. HIV-specific CD8+ T cell immune responses and viral replication
3. Virus-specific CD8+ cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
4. Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers
5. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors
6. High levels of anti-Human Immunodeficiency Virus Type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors
7. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells
8. Higher macrophage inflammatory protein MIP-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection
9. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual
10. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors
11. Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination
12. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
13. Identification of SIV env-specific CTL in the jejunal mucosa in vaginally exposed, seronegative rhesus macaques (Macaca mulatta)
14. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus
15. Effects of in vivo CD8+ T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
16. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
17. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes
18. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge
19. Immunofluorescent localization of equine infectious anemia virus in tissue
20. Equine endothelial cells support productive infection of equine infectious anemia virus
21. Endothelial cell infection in vivo by equine infectious anaemia virus
22. Efficacy of inactivated whole-virus and sub-unit vaccines in preventing infection and disease caused by equine infectious anemia virus
23. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins
24. Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses
25. Frequency of memory cytotoxic T lymphocytes to equine infectious anemia virus proteins in blood from carrier horses
26. Detection and induction of equine infectious anemia virus-specific cytotoxic T lymphocyte responses by use of recombinant retroviral vectors
27. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8+ T lymphocyte activation
28. Macromolecular assemblage in the design of a synthetic AIDS vaccine
29. Comparison of adjuvant formulation for cytotoxic T cell induction using synthetic peptides
30. Processing and delivery of peptides presented by MHC class I molecules
31. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
32. Localization of the cell activator lipopeptide in bone marrow-derived macrophages by electron energy loss spectroscopy (EELS)
33. Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues
34. Activation of bone marrow-derived mouse macrophages by bacterial lipopeptide: Cytokine production, phagocytosis and Ia expression
35. Accessory signalling by B7-1 for T cell activation induced by anti-CD2: Evidence for IL-2-independent CTL generation and CsA-resistant cytokine production
36. Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus
37. Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6
38. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals
39. Multiepitopic B- and T cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
40. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine
41. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection
42. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids
43. Population studies on the ELA system in American standard bred and thorough bred mares
44. Identification and genetics of horse lymphocyte alloantigens
45. The equine major histocompatibility complex
46. Immunogenetics of the horse
47. The interaction of nominal antigen with T cell antigen receptors. Part I. Specific binding of multivalent nominal antigen to cytolytic T cell clones
48. Extension of HLA-A*0201-restricted minimal epitope by N-epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells
49. Supra-agonist peptides enhance the reactivation of memory CTL responses
50. Peptides naturally presented by MHC class I molecules
51. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides
52. A synthetic analogue of Escherichia coli lipoprotein, tripalmitoyl pentapeptide, constitutes a potent immune adjuvant
53. Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation
54. Synthetic peptides coupled to the lipotripeptide P3CSS induce in vivo B and T helper cell responses to HIV-1 reverse transcriptase
55. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the co-stimulating support provided by helper T cells and lipo-amino acid
56. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells